Boryung Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 03:06 am EST
Share
Boryung Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 85.91 million compared to KRW 414.54 million a year ago. Net income was KRW 21,952.75 million compared to KRW 20,565.74 million a year ago. Basic earnings per share from continuing operations was KRW 333 compared to KRW 316 a year ago. Diluted earnings per share from continuing operations was KRW 333 compared to KRW 316 a year ago. Basic earnings per share was KRW 333 compared to KRW 316 a year ago.
For the nine months, sales was KRW 314.52 million compared to KRW 631.44 million a year ago. Net income was KRW 48,233.74 million compared to KRW 37,367.22 million a year ago. Basic earnings per share from continuing operations was KRW 732 compared to KRW 609 a year ago. Diluted earnings per share from continuing operations was KRW 730 compared to KRW 607 a year ago. Basic earnings per share was KRW 732 compared to KRW 609 a year ago. Diluted earnings per share was KRW 730 compared to KRW 607 a year ago.
Boryung Corp, formerly Boryung Pharm Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.